Envisioning an end to blindness

About Broadwing Bio

We are advancing antibody therapies to treat major causes of adult vision loss.

With robust antibody-based drugs directed to genetically validated targets, we will develop therapies that preserve vision to meaningfully impact people's lives.

Logo icon - basic iconified eye

Genetically driven

We are advancing a pipeline directed to genetically validated ophthalmology targets. Building on insights into disease protection from naturally occurring genetic variants in the human population, we will change the treatment of ocular disease.

Logo icon - basic iconified eye

Drug discovery expertise

Broadwing’s team brings deep expertise in antibody discovery and development. We leverage Alloy Therapeutic’s industry-leading capabilities for antibody generation and develop therapies with a focus on maximizing the potential benefit to patients and providers.

Logo icon - basic iconified eye

Lift our success

Broadwing Bio was founded with a mission of ending blindness. To ensure our success, we will engage collaborative partners that share our vision to accelerate bringing medicines to patients in need.

What we do

Developing therapies for individuals with Geographic Atrophy and Glaucoma

Geographic Atrophy

Geographic Atrophy

Geographic Atrophy (GA) is an advanced form of Age-Related Macular Degeneration characterized by progressive irreversible vision loss for which there is no current treatment option. The atrophy is a loss of photoreceptors in the central visual field. As the progresslive atrophy encroaches on the fovea, central vision is impacted. This can lead to disability and blindness. The goal of interventional therapy for GA is to halt or slow the progression of photoreceptor loss, preserving vision.



Glaucoma is a group of diseases impacting the optic nerve and involving the loss of retinal ganglion cells. Overproduction of aqueous humor or reduced outflow increases intraocular pressure, damaging the optic nerve and diminishing peripheral vision. The goal of interventional therapy for glaucoma is to prevent optic nerve damage and preserve vision.


Broadwing has a
and patient-focused
therapeutic approach

Our Team

Andrew Peterson, Ph.D.

Founder, CEO and board member, former senior director of molecular biology and metabolic disease at Genentech.

Jennifer Cygan, Ph.D.

Founder, former head of project team leaders at Calico and head of technology platforms business development at Genentech.

Manuel Rivas, D.Phil

Founder and scientific advisory board member, assistant professor in the Department of Biomedical Data Science at Stanford University.

Atul Dandekar

Broadwing board member and chief strategy officer at Maze Therapeutics, as global franchise head for ophthalmology at Genentech and Roche helped develop faricimab and Port Delivery System with ranibizumab (PDS), novel treatment options for diabetic macular edema and neovascular age-related macular degeneration.

Errik Anderson

Board member and CEO of Alloy Therapeutics, co-founder of Adimab, Compass and Alector Therapeutics.

Maarten Hoek, Ph.D.

Scientific steering committee member and senior director, biology at Maze, former director of cardiorenal and fibrotic disease at Merck.

Piotr Bobrowicz, Ph.D.

Scientific steering committee member and chief scientific officer at Alloy, former chief scientific officer at Compass Therapeutics and director of antibody engineering and head of strain engineering and open innovation at Adimab.

John Atkinson, M.D.

Scientific advisory board member, professor, Division of Biology and Biomedical Sciences, Washington University.

Dan Stamer, Ph.D.

Scientific advisory board member, Joseph A.C. Wadsworth professor of ophthalmology, Duke University School of Medicine.

Logo icon - basic iconified eye

Join our team

We are growing our team of drug discovery scientists who share our passion for developing medicines to end blindness. Please find our current openings here:

Scientist - Senior Scientist, Biology

Senior Research Associate, Biology

Senior Research Associate, Biochemistry

Logo icon - basic iconified eye

Learn more about our mission

If you are interested in learning more about our therapeutic programs and opportunities for partnering, please contact us at: